Literature DB >> 30207914

Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.

Emmanuel S Antonarakis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30207914     DOI： 10.1056/NEJMcibr1808772

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

2.  Therapeutic targeting of the DNA damage response in prostate cancer.

Authors:  Catherine H Marshall; Emmanuel S Antonarakis
Journal:  Curr Opin Oncol       Date:  2020-05       Impact factor: 3.645

3.  Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.

Authors:  Pedro Barata; Elisa Ledet; Charlotte Manogue; Patrick Cotogno; Kendra Harris; Brian Lewis; Jodi Layton; Oliver Sartor
Journal:  Oncologist       Date:  2020-07-12

4.  Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Authors:  Ethan S Sokol; Dean Pavlick; Garrett M Frampton; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Tamara L Lotan; Drew M Pardoll; Jon H Chung; Emmanuel S Antonarakis
Journal:  Oncologist       Date:  2019-07-10

Review 5.  Is There a Role for Immunotherapy in Prostate Cancer?

Authors:  Alessandro Rizzo; Veronica Mollica; Alessia Cimadamore; Matteo Santoni; Marina Scarpelli; Francesca Giunchi; Liang Cheng; Antonio Lopez-Beltran; Michelangelo Fiorentino; Rodolfo Montironi; Francesco Massari
Journal:  Cells       Date:  2020-09-08       Impact factor: 6.600

6.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

Authors:  Emmanuel S Antonarakis; Pedro Isaacsson Velho; Wei Fu; Hao Wang; Neeraj Agarwal; Victor Sacristan Santos; Benjamin L Maughan; Roberto Pili; Nabil Adra; Cora N Sternberg; Panagiotis J Vlachostergios; Scott T Tagawa; Alan H Bryce; Andrea L McNatty; Zachery R Reichert; Robert Dreicer; Oliver Sartor; Tamara L Lotan; Maha Hussain
Journal:  JCO Precis Oncol       Date:  2020-04-21

7.  Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Authors:  Emmanuel S Antonarakis; Jun Luo; Andrew J Armstrong; Landon C Brown; Changxue Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-24       Impact factor: 5.554

Review 8.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.

Authors:  Michael T Schweizer; Gavin Ha; Roman Gulati; Landon C Brown; Rana R McKay; Tanya Dorff; Anna C H Hoge; Jonathan Reichel; Pankaj Vats; Deepak Kilari; Vaibhav Patel; William K Oh; Arul Chinnaiyan; Colin C Pritchard; Andrew J Armstrong; R Bruce Montgomery; Ajjai Alva
Journal:  JCO Precis Oncol       Date:  2020-04-21

10.  Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.

Authors:  Mark C Markowski; Eugene Shenderov; Mario A Eisenberger; Sushant Kachhap; Drew M Pardoll; Samuel R Denmeade; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2020-01-23       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.